Vandekerkhove Gillian, Chi Kim N, Wyatt Alexander W
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, 2660 Oak Street, Vancouver, British Columbia, Canada V6H 3Z6.
Department of Medical Oncology, British Columbia Cancer Agency, British Columbia, Canada.
Cancer Genet. 2018 Dec;228-229:151-158. doi: 10.1016/j.cancergen.2017.08.003. Epub 2017 Aug 25.
The therapeutic landscape of advanced prostate cancer (PCa) has rapidly expanded in recent years. Despite significant improvements in patient overall survival, it remains challenging to determine the optimal therapy and sequence of therapies for individual patients. The development of molecular biomarkers will be key for patient stratification, and for monitoring response and resistance to therapy. In this context, minimally-invasive blood-based "liquid" biopsies are attractive as a practical surrogate for solid tumor tissue, providing a window into metastatic disease. Circulating tumor cells and circulating cell-free tumor DNA in particular have demonstrated remarkable potential to inform on PCa patient outcomes through the detection of specific genomic and transcriptomic alterations. This review covers recent advances in the development of clinically-informative liquid biomarkers for advanced PCa.
近年来，晚期前列腺癌（PCa）的治疗领域迅速扩展。尽管患者的总生存率有了显著提高，但确定个体患者的最佳治疗方案及治疗顺序仍具有挑战性。分子生物标志物的开发对于患者分层以及监测治疗反应和耐药性至关重要。在这种背景下，基于血液的微创“液体”活检作为实体瘤组织的实用替代方法具有吸引力，为转移性疾病提供了一个窗口。特别是循环肿瘤细胞和循环游离肿瘤DNA，通过检测特定的基因组和转录组改变，已显示出在预测PCa患者预后方面的巨大潜力。本综述涵盖了晚期PCa临床信息丰富的液体生物标志物开发的最新进展。
